-
1
-
-
84881479047
-
Liquid biopsy: monitoring cancer-genetics in the blood
-
3836314
-
Crowley E, Di Nicolantonio F, Loupakis F, Bardelli A, Liquid biopsy: monitoring cancer-genetics in the blood. Nat Rev Clin Oncol. 2013;10(8):472–84. doi: 10.1038/nrclinonc.2013.11023836314
-
(2013)
Nat Rev Clin Oncol
, vol.10
, Issue.8
, pp. 472-484
-
-
Crowley, E.1
Di Nicolantonio, F.2
Loupakis, F.3
Bardelli, A.4
-
2
-
-
23944459558
-
Perspective: a program to improve protein biomarker discovery for cancer
-
6083259
-
Aebersold R, Anderson L, Caprioli R, Druker B, Hartwell L, Smith R, Perspective: a program to improve protein biomarker discovery for cancer. J Proteome Res. 2005;4(4):1104–9. doi: 10.1021/pr050027n16083259
-
(2005)
J Proteome Res
, vol.4
, Issue.4
, pp. 1104-1109
-
-
Aebersold, R.1
Anderson, L.2
Caprioli, R.3
Druker, B.4
Hartwell, L.5
Smith, R.6
-
3
-
-
0025134708
-
A risk of malignancy index incorporating CA 125, ultrasound and menopausal status for the accurate preoperative diagnosis of ovarian cancer
-
223684
-
Jacobs I, Oram D, Fairbanks J, Turner J, Frost C, Grudzinskas JG, A risk of malignancy index incorporating CA 125, ultrasound and menopausal status for the accurate preoperative diagnosis of ovarian cancer. Br J Obstet Gynaecol. 1990;97(10):922–9. 2223684
-
(1990)
Br J Obstet Gynaecol
, vol.97
, Issue.10
, pp. 922-929
-
-
Jacobs, I.1
Oram, D.2
Fairbanks, J.3
Turner, J.4
Frost, C.5
Grudzinskas, J.G.6
-
4
-
-
55349134617
-
National Academy of Clinical Biochemistry laboratory medicine practice guidelines for use of tumor markers in testicular, prostate, colorectal, breast, and ovarian cancers
-
9042984
-
Sturgeon CM, Duffy MJ, Stenman UH, Lilja H, Brunner N, Chan DW, et al. National Academy of Clinical Biochemistry laboratory medicine practice guidelines for use of tumor markers in testicular, prostate, colorectal, breast, and ovarian cancers. Clin Chem. 2008;54(12):e11–79. doi: 10.1373/clinchem.2008.10560119042984
-
(2008)
Clin Chem
, vol.54
, Issue.12
, pp. e11-79
-
-
Sturgeon, C.M.1
Duffy, M.J.2
Stenman, U.H.3
Lilja, H.4
Brunner, N.5
Chan, D.W.6
-
5
-
-
84953269496
-
Clinical use of cancer biomarkers in epithelial ovarian cancer: updated guidelines from the European Group on Tumor Markers
-
6588231
-
Soletormos G, Duffy MJ, Othman Abu Hassan S, Verheijen RH, Tholander B, Bast RC, Jret al. Clinical use of cancer biomarkers in epithelial ovarian cancer: updated guidelines from the European Group on Tumor Markers. Int J Gynecol Cancer. 2016;26(1):43–51. doi: 10.1097/IGC.000000000000058626588231
-
(2016)
Int J Gynecol Cancer
, vol.26
, Issue.1
, pp. 43-51
-
-
Soletormos, G.1
Duffy, M.J.2
Othman Abu Hassan, S.3
Verheijen, R.H.4
Tholander, B.5
Bast, R.C.6
-
6
-
-
79958036419
-
Effect of screening on ovarian cancer mortality: the Prostate, Lung, Colorectal and Ovarian (PLCO) Cancer Screening Randomized Controlled Trial
-
1642681
-
Buys SS, Partridge E, Black A, Johnson CC, Lamerato L, Isaacs C, et al. Effect of screening on ovarian cancer mortality: the Prostate, Lung, Colorectal and Ovarian (PLCO) Cancer Screening Randomized Controlled Trial. JAMA. 2011;305(22):2295–303. doi: 10.1001/jama.2011.76621642681
-
(2011)
JAMA
, vol.305
, Issue.22
, pp. 2295-2303
-
-
Buys, S.S.1
Partridge, E.2
Black, A.3
Johnson, C.C.4
Lamerato, L.5
Isaacs, C.6
-
7
-
-
84959863810
-
Ovarian cancer screening and mortality in the UK Collaborative Trial of Ovarian Cancer Screening (UKCTOCS): a randomised controlled trial
-
6707054
-
Jacobs IJ, Menon U, Ryan A, Gentry-Maharaj A, Burnell M, Kalsi JK, et al. Ovarian cancer screening and mortality in the UK Collaborative Trial of Ovarian Cancer Screening (UKCTOCS): a randomised controlled trial. Lancet. 2016;387(10022):945–56. doi: 10.1016/S0140-6736(15)01224-626707054
-
(2016)
Lancet
, vol.387
, Issue.10022
, pp. 945-956
-
-
Jacobs, I.J.1
Menon, U.2
Ryan, A.3
Gentry-Maharaj, A.4
Burnell, M.5
Kalsi, J.K.6
-
8
-
-
0036742575
-
The effect of ascites, mass volume, and peritoneal carcinomatosis on serum CA125 levels in patients with ovarian carcinoma
-
2366659
-
Saygili U, Guclu S, Uslu T, Erten O, Dogan E, The effect of ascites, mass volume, and peritoneal carcinomatosis on serum CA125 levels in patients with ovarian carcinoma. Int J Gynecol Cancer. 2002;12(5):438–42. 12366659
-
(2002)
Int J Gynecol Cancer
, vol.12
, Issue.5
, pp. 438-442
-
-
Saygili, U.1
Guclu, S.2
Uslu, T.3
Erten, O.4
Dogan, E.5
-
9
-
-
77953406093
-
Role of CA125 in predicting ovarian cancer survival—a review of the epidemiological literature
-
9818123,.;:
-
Gupta D, Lis CG, Role of CA125 in predicting ovarian cancer survival—a review of the epidemiological literature. J Ovarian Res. 2009;2:13. doi: 10.1186/1757-2215-2-1319818123
-
(2009)
J Ovarian Res
, vol.2
, pp. 13
-
-
Gupta, D.1
Lis, C.G.2
-
10
-
-
56449098987
-
Serum and tissue biomarkers as predictive and prognostic variables in epithelial ovarian cancer
-
8595727
-
Gadducci A, Cosio S, Tana R, Genazzani AR, Serum and tissue biomarkers as predictive and prognostic variables in epithelial ovarian cancer. Crit Rev Oncol Hematol. 2009;69(1):12–27. doi: 10.1016/j.critrevonc.2008.05.00118595727
-
(2009)
Crit Rev Oncol Hematol
, vol.69
, Issue.1
, pp. 12-27
-
-
Gadducci, A.1
Cosio, S.2
Tana, R.3
Genazzani, A.R.4
-
11
-
-
0042334866
-
Rapid clearance of plasma Epstein-Barr virus DNA after surgical treatment of nasopharyngeal carcinoma
-
2960110
-
To EW, Chan KC, Leung SF, Chan LY, To KF, Chan AT, et al. Rapid clearance of plasma Epstein-Barr virus DNA after surgical treatment of nasopharyngeal carcinoma. Clin Cancer Res. 2003;9(9):3254–9. 12960110
-
(2003)
Clin Cancer Res
, vol.9
, Issue.9
, pp. 3254-3259
-
-
To, E.W.1
Chan, K.C.2
Leung, S.F.3
Chan, L.Y.4
To, K.F.5
Chan, A.T.6
-
12
-
-
51349141191
-
Circulating mutant DNA to assess tumor dynamics
-
8670422
-
Diehl F, Schmidt K, Choti MA, Romans K, Goodman S, Li M, et al. Circulating mutant DNA to assess tumor dynamics. Nat Med. 2008;14(9):985–90. doi: 10.1038/nm.178918670422
-
(2008)
Nat Med
, vol.14
, Issue.9
, pp. 985-990
-
-
Diehl, F.1
Schmidt, K.2
Choti, M.A.3
Romans, K.4
Goodman, S.5
Li, M.6
-
13
-
-
0028225017
-
Soluble normal and mutated DNA sequences from single-copy genes in human blood
-
118388
-
Sorenson GD, Pribish DM, Valone FH, Memoli VA, Bzik DJ, Yao SL, Soluble normal and mutated DNA sequences from single-copy genes in human blood. Cancer Epidemiol Biomarkers Prev. 1994;3(1):67–71. 8118388
-
(1994)
Cancer Epidemiol Biomarkers Prev
, vol.3
, Issue.1
, pp. 67-71
-
-
Sorenson, G.D.1
Pribish, D.M.2
Valone, F.H.3
Memoli, V.A.4
Bzik, D.J.5
Yao, S.L.6
-
14
-
-
0028241030
-
Point mutations of the N-ras gene in the blood plasma DNA of patients with myelodysplastic syndrome or acute myelogenous leukaemia
-
918071
-
Vasioukhin V, Anker P, Maurice P, Lyautey J, Lederrey C, Stroun M, Point mutations of the N-ras gene in the blood plasma DNA of patients with myelodysplastic syndrome or acute myelogenous leukaemia. Br J Haematol. 1994;86(4):774–9. 7918071
-
(1994)
Br J Haematol
, vol.86
, Issue.4
, pp. 774-779
-
-
Vasioukhin, V.1
Anker, P.2
Maurice, P.3
Lyautey, J.4
Lederrey, C.5
Stroun, M.6
-
15
-
-
84896371874
-
Detection of circulating tumor DNA in early- and late-stage human malignancies
-
4553385,..; ():
-
Bettegowda C, Sausen M, Leary RJ, Kinde I, Wang Y, Agrawal N, et al. Detection of circulating tumor DNA in early- and late-stage human malignancies. Sci Transl Med. 2014;6(224):224ra24. doi: 10.1126/scitranslmed.300709424553385
-
(2014)
Sci Transl Med
, vol.6
, Issue.224
, pp. 224ra24
-
-
Bettegowda, C.1
Sausen, M.2
Leary, R.J.3
Kinde, I.4
Wang, Y.5
Agrawal, N.6
-
16
-
-
84875520648
-
Analysis of circulating tumor DNA to monitor metastatic breast cancer
-
3484797
-
Dawson SJ, Tsui DW, Murtaza M, Biggs H, Rueda OM, Chin SF, et al. Analysis of circulating tumor DNA to monitor metastatic breast cancer. N Engl J Med. 2013;368(13):1199–209. doi: 10.1056/NEJMoa121326123484797
-
(2013)
N Engl J Med
, vol.368
, Issue.13
, pp. 1199-1209
-
-
Dawson, S.J.1
Tsui, D.W.2
Murtaza, M.3
Biggs, H.4
Rueda, O.M.5
Chin, S.F.6
-
17
-
-
84903218109
-
An ultrasensitive method for quantitating circulating tumor DNA with broad patient coverage
-
4705333
-
Newman AM, Bratman SV, To J, Wynne JF, Eclov NC, Modlin LA, et al. An ultrasensitive method for quantitating circulating tumor DNA with broad patient coverage. Nat Med. 2014;20(5):548–54. doi: 10.1038/nm.351924705333
-
(2014)
Nat Med
, vol.20
, Issue.5
, pp. 548-554
-
-
Newman, A.M.1
Bratman, S.V.2
To, J.3
Wynne, J.F.4
Eclov, N.C.5
Modlin, L.A.6
-
18
-
-
63449103435
-
Single-molecule detection of epidermal growth factor receptor mutations in plasma by microfluidics digital PCR in non-small cell lung cancer patients
-
9276259
-
Yung TK, Chan KC, Mok TS, Tong J, To KF, Lo YM, Single-molecule detection of epidermal growth factor receptor mutations in plasma by microfluidics digital PCR in non-small cell lung cancer patients. Clin Cancer Res. 2009;15(6):2076–84. doi: 10.1158/1078-0432.CCR-08-262219276259
-
(2009)
Clin Cancer Res
, vol.15
, Issue.6
, pp. 2076-2084
-
-
Yung, T.K.1
Chan, K.C.2
Mok, T.S.3
Tong, J.4
To, K.F.5
Lo, Y.M.6
-
19
-
-
84898542288
-
Liquid biopsies: genotyping circulating tumor DNA
-
4449238
-
Diaz LA, JrBardelli A, Liquid biopsies: genotyping circulating tumor DNA. J Clin Oncol. 2014;32(6):579–86. doi: 10.1200/JCO.2012.45.201124449238
-
(2014)
J Clin Oncol
, vol.32
, Issue.6
, pp. 579-586
-
-
Diaz, L.A.1
Bardelli, A.2
-
20
-
-
28044468634
-
Detection and quantification of mutations in the plasma of patients with colorectal tumors
-
6258065
-
Diehl F, Li M, Dressman D, He Y, Shen D, Szabo S, et al. Detection and quantification of mutations in the plasma of patients with colorectal tumors. Proc Natl Acad Sci U S A. 2005;102(45):16368–73. doi: 10.1073/pnas.050790410216258065
-
(2005)
Proc Natl Acad Sci U S A
, vol.102
, Issue.45
, pp. 16368-16373
-
-
Diehl, F.1
Li, M.2
Dressman, D.3
He, Y.4
Shen, D.5
Szabo, S.6
-
21
-
-
84861746437
-
Noninvasive identification and monitoring of cancer mutations by targeted deep sequencing of plasma DNA
-
2649089,..; ():
-
Forshew T, Murtaza M, Parkinson C, Gale D, Tsui DW, Kaper F, et al. Noninvasive identification and monitoring of cancer mutations by targeted deep sequencing of plasma DNA. Sci Transl Med. 2012;4(136):136ra68. doi: 10.1126/scitranslmed.300372622649089
-
(2012)
Sci Transl Med
, vol.4
, Issue.136
, pp. 136ra68
-
-
Forshew, T.1
Murtaza, M.2
Parkinson, C.3
Gale, D.4
Tsui, D.W.5
Kaper, F.6
-
22
-
-
84941630950
-
Circulating tumor DNA as an early marker of therapeutic response in patients with metastatic colorectal cancer
-
5851626
-
Tie J, Kinde I, Wang Y, Wong HL, Roebert J, Christie M, et al. Circulating tumor DNA as an early marker of therapeutic response in patients with metastatic colorectal cancer. Ann Oncol. 2015;26(8):1715–22. doi: 10.1093/annonc/mdv17725851626
-
(2015)
Ann Oncol
, vol.26
, Issue.8
, pp. 1715-1722
-
-
Tie, J.1
Kinde, I.2
Wang, Y.3
Wong, H.L.4
Roebert, J.5
Christie, M.6
-
23
-
-
77950965840
-
Driver mutations in TP53 are ubiquitous in high grade serous carcinoma of the ovary
-
0229506
-
Ahmed AA, Etemadmoghadam D, Temple J, Lynch AG, Riad M, Sharma R, et al. Driver mutations in TP53 are ubiquitous in high grade serous carcinoma of the ovary. J Pathol. 2010;221(1):49–56. doi: 10.1002/path.269620229506
-
(2010)
J Pathol
, vol.221
, Issue.1
, pp. 49-56
-
-
Ahmed, A.A.1
Etemadmoghadam, D.2
Temple, J.3
Lynch, A.G.4
Riad, M.5
Sharma, R.6
-
24
-
-
79959838081
-
Integrated genomic analyses of ovarian carcinoma
-
1720365
-
Cancer Genome Atlas Research NetworkIntegrated genomic analyses of ovarian carcinoma. Nature. 2011;474(7353):609–15. doi: 10.1038/nature1016621720365
-
(2011)
Nature
, vol.474
, Issue.7353
, pp. 609-615
-
-
-
25
-
-
85009202117
-
Optimized p53 immunohistochemistry is an accurate predictor of TP53 mutation in ovarian carcinoma
-
7840695
-
Köbel M, Piskorz AM, Lee S, Lui S, LePage C, Marass F, et al. Optimized p53 immunohistochemistry is an accurate predictor of TP53 mutation in ovarian carcinoma. J Pathol Clin Res. 2016;2(4):247–58. doi: 10.1002/cjp2.5327840695
-
(2016)
J Pathol Clin Res
, vol.2
, Issue.4
, pp. 247-258
-
-
Köbel, M.1
Piskorz, A.M.2
Lee, S.3
Lui, S.4
LePage, C.5
Marass, F.6
-
26
-
-
0019790278
-
Reactivity of a monoclonal antibody with human ovarian carcinoma
-
028788
-
Bast RC, JrFeeney M, Lazarus H, Nadler LM, Colvin RB, Knapp RC, Reactivity of a monoclonal antibody with human ovarian carcinoma. J Clin Invest. 1981;68(5):1331–7. doi: 10.1172/JCI1103807028788
-
(1981)
J Clin Invest
, vol.68
, Issue.5
, pp. 1331-1337
-
-
Bast, R.C.1
Feeney, M.2
Lazarus, H.3
Nadler, L.M.4
Colvin, R.B.5
Knapp, R.C.6
-
27
-
-
74249095507
-
Current state of biomarker development for clinical application in epithelial ovarian cancer
-
9879639
-
Moore RG, MacLaughlan S, Bast RC, JrCurrent state of biomarker development for clinical application in epithelial ovarian cancer. Gynecol Oncol. 2010;116(2):240–5. doi: 10.1016/j.ygyno.2009.09.04119879639
-
(2010)
Gynecol Oncol
, vol.116
, Issue.2
, pp. 240-245
-
-
Moore, R.G.1
MacLaughlan, S.2
Bast, R.C.3
-
28
-
-
24344497920
-
Tumor-specific p53 sequences in blood and peritoneal fluid of women with epithelial ovarian cancer
-
Swisher EM, Wollan M, Mahtani SM, Willner JB, Garcia R, Goff BA, et al. Tumor-specific p53 sequences in blood and peritoneal fluid of women with epithelial ovarian cancer. Am J Obstet Gynecol. 2005;193(3 Pt 1):662–7.
-
(2005)
Am J Obstet Gynecol
, vol.193
, Issue.3
, pp. 662-667
-
-
Swisher, E.M.1
Wollan, M.2
Mahtani, S.M.3
Willner, J.B.4
Garcia, R.5
Goff, B.A.6
-
29
-
-
2942594294
-
Detection of p53 mutations in the plasma DNA of patients with ovarian cancer
-
5228418
-
Otsuka J, Okuda T, Sekizawa A, Amemiya S, Saito H, Okai T, et al. Detection of p53 mutations in the plasma DNA of patients with ovarian cancer. Int J Gynecol Cancer. 2004;14(3):459–64. doi: 10.1111/j.1048-891x.2004.014305.x15228418
-
(2004)
Int J Gynecol Cancer
, vol.14
, Issue.3
, pp. 459-464
-
-
Otsuka, J.1
Okuda, T.2
Sekizawa, A.3
Amemiya, S.4
Saito, H.5
Okai, T.6
-
30
-
-
84956949472
-
Personalized circulating tumor DNA biomarkers dynamically predict treatment response and survival in gynecologic cancers
-
6717006,..; ():
-
Pereira E, Camacho-Vanegas O, Anand S, Sebra R, Catalina Camacho S, Garnar-Wortzel L, et al. Personalized circulating tumor DNA biomarkers dynamically predict treatment response and survival in gynecologic cancers. PLoS ONE. 2015;10(12):e0145754. doi: 10.1371/journal.pone.014575426717006
-
(2015)
PLoS ONE
, vol.10
, Issue.12
, pp. e0145754
-
-
Pereira, E.1
Camacho-Vanegas, O.2
Anand, S.3
Sebra, R.4
Catalina Camacho, S.5
Garnar-Wortzel, L.6
-
31
-
-
35648939797
-
The Strengthening the Reporting of Observational Studies in Epidemiology (STROBE) statement: guidelines for reporting observational studies
-
7941714,..; ():
-
von Elm E, Altman DG, Egger M, Pocock SJ, Gotzsche PC, Vandenbroucke JP, et al. The Strengthening the Reporting of Observational Studies in Epidemiology (STROBE) statement: guidelines for reporting observational studies. PLoS Med. 2007;4(10):e296. doi: 10.1371/journal.pmed.004029617941714
-
(2007)
PLoS Med
, vol.4
, Issue.10
, pp. e296
-
-
von Elm, E.1
Altman, D.G.2
Egger, M.3
Pocock, S.J.4
Gotzsche, P.C.5
Vandenbroucke, J.P.6
-
32
-
-
23844534811
-
Reporting recommendations for tumor marker prognostic studies (REMARK)
-
6106022
-
McShane LM, Altman DG, Sauerbrei W, Taube SE, Gion M, Clark GM, et al. Reporting recommendations for tumor marker prognostic studies (REMARK). J Natl Cancer Inst. 2005;97(16):1180–4. doi: 10.1093/jnci/dji23716106022
-
(2005)
J Natl Cancer Inst
, vol.97
, Issue.16
, pp. 1180-1184
-
-
McShane, L.M.1
Altman, D.G.2
Sauerbrei, W.3
Taube, S.E.4
Gion, M.5
Clark, G.M.6
-
33
-
-
57849117384
-
New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1)
-
9097774
-
Eisenhauer EA, Therasse P, Bogaerts J, Schwartz LH, Sargent D, Ford R, et al. New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1). Eur J Cancer. 2009;45(2):228–47. doi: 10.1016/j.ejca.2008.10.02619097774
-
(2009)
Eur J Cancer
, vol.45
, Issue.2
, pp. 228-247
-
-
Eisenhauer, E.A.1
Therasse, P.2
Bogaerts, J.3
Schwartz, L.H.4
Sargent, D.5
Ford, R.6
-
34
-
-
33749993417
-
The consensus coding sequences of human breast and colorectal cancers
-
6959974
-
Sjoblom T, Jones S, Wood LD, Parsons DW, Lin J, Barber TD, et al. The consensus coding sequences of human breast and colorectal cancers. Science. 2006;314(5797):268–74. doi: 10.1126/science.113342716959974
-
(2006)
Science
, vol.314
, Issue.5797
, pp. 268-274
-
-
Sjoblom, T.1
Jones, S.2
Wood, L.D.3
Parsons, D.W.4
Lin, J.5
Barber, T.D.6
-
35
-
-
84870510405
-
Sequential genetic change at the TP53 and chemokine receptor CXCR4 locus during transformation of human ovarian surface epithelium
-
2266861
-
Archibald KM, Kulbe H, Kwong J, Chakravarty P, Temple J, Chaplin T, et al. Sequential genetic change at the TP53 and chemokine receptor CXCR4 locus during transformation of human ovarian surface epithelium. Oncogene. 2012;31(48):4987–95. doi: 10.1038/onc.2011.65322266861
-
(2012)
Oncogene
, vol.31
, Issue.48
, pp. 4987-4995
-
-
Archibald, K.M.1
Kulbe, H.2
Kwong, J.3
Chakravarty, P.4
Temple, J.5
Chaplin, T.6
-
36
-
-
11144356618
-
Re: new guidelines to evaluate the response to treatment in solid tumors (ovarian cancer)
-
Rustin GJ, Quinn M, Thigpen T, du Bois A, Pujade-Lauraine E, Jakobsen A, et al. Re: new guidelines to evaluate the response to treatment in solid tumors (ovarian cancer). J Natl Cancer Inst. 2004;96(6):487–8.
-
(2004)
J Natl Cancer Inst
, vol.96
, Issue.6
, pp. 487-488
-
-
Rustin, G.J.1
Quinn, M.2
Thigpen, T.3
du Bois, A.4
Pujade-Lauraine, E.5
Jakobsen, A.6
-
37
-
-
84865677634
-
Cell-free DNA level as a prognostic biomarker for epithelial ovarian cancer
-
2843932
-
No JH, Kim K, Park KH, Kim YB, Cell-free DNA level as a prognostic biomarker for epithelial ovarian cancer. Anticancer Res. 2012;32(8):3467–71. 22843932
-
(2012)
Anticancer Res
, vol.32
, Issue.8
, pp. 3467-3471
-
-
No, J.H.1
Kim, K.2
Park, K.H.3
Kim, Y.B.4
-
38
-
-
84949058124
-
Circulating free DNA concentration is an independent prognostic biomarker in lung cancer
-
6493785
-
Tissot C, Toffart AC, Villar S, Souquet PJ, Merle P, Moro-Sibilot D, et al. Circulating free DNA concentration is an independent prognostic biomarker in lung cancer. Eur Respir J. 2015;46(6):1773–80. doi: 10.1183/13993003.00676-201526493785
-
(2015)
Eur Respir J
, vol.46
, Issue.6
, pp. 1773-1780
-
-
Tissot, C.1
Toffart, A.C.2
Villar, S.3
Souquet, P.J.4
Merle, P.5
Moro-Sibilot, D.6
-
39
-
-
84975753826
-
-
[cited 2016 Nov 18]. Available from:. Vienna R Foundation for Statistical Computing
-
R Core TeamR: a language and environment for statistical computing. Vienna: R Foundation for Statistical Computing; 2016 [cited 2016 Nov 18]. Available from: https://www.R-project.org/.
-
(2016)
R: a language and environment for statistical computing
-
-
-
40
-
-
84901017078
-
Repeatability of quantitative FDG-PET/CT and contrast-enhanced CT in recurrent ovarian carcinoma: test-retest measurements for tumor FDG uptake, diameter, and volume
-
4573555
-
Rockall AG, Avril N, Lam R, Iannone R, Mozley PD, Parkinson C, et al. Repeatability of quantitative FDG-PET/CT and contrast-enhanced CT in recurrent ovarian carcinoma: test-retest measurements for tumor FDG uptake, diameter, and volume. Clin Cancer Res. 2014;20(10):2751–60. doi: 10.1158/1078-0432.CCR-13-263424573555
-
(2014)
Clin Cancer Res
, vol.20
, Issue.10
, pp. 2751-2760
-
-
Rockall, A.G.1
Avril, N.2
Lam, R.3
Iannone, R.4
Mozley, P.D.5
Parkinson, C.6
-
41
-
-
0036329541
-
Tumor volumetry as predictive and prognostic factor in the management of ovarian cancer
-
2168891
-
Andreopoulou E, Andreopoulos D, Adamidis K, Fountzila-Kalogera A, Fountzilas G, Dimopoulos MA, et al. Tumor volumetry as predictive and prognostic factor in the management of ovarian cancer. Anticancer Res. 2002;22(3):1903–8. 12168891
-
(2002)
Anticancer Res
, vol.22
, Issue.3
, pp. 1903-1908
-
-
Andreopoulou, E.1
Andreopoulos, D.2
Adamidis, K.3
Fountzila-Kalogera, A.4
Fountzilas, G.5
Dimopoulos, M.A.6
-
42
-
-
0030698757
-
Predictors of response to subsequent chemotherapy in platinum pretreated ovarian cancer: a multivariate analysis of 704 patients
-
402168
-
Eisenhauer EA, Vermorken JB, van Glabbeke M, Predictors of response to subsequent chemotherapy in platinum pretreated ovarian cancer: a multivariate analysis of 704 patients. Ann Oncol. 1997;8(10):963–8. 9402168
-
(1997)
Ann Oncol
, vol.8
, Issue.10
, pp. 963-968
-
-
Eisenhauer, E.A.1
Vermorken, J.B.2
van Glabbeke, M.3
-
43
-
-
84958149811
-
Prognostic value of (18)F-FDG PET/CT volumetric parameters in recurrent epithelial ovarian cancer
-
6541072
-
Mayoral M, Fernandez-Martinez A, Vidal L, Fuster D, Aya F, Pavia J, et al. Prognostic value of (18)F-FDG PET/CT volumetric parameters in recurrent epithelial ovarian cancer. Rev Esp Med Nucl Imagen Mol. 2016;35(2):88–95. doi: 10.1016/j.remn.2015.08.00526541072
-
(2016)
Rev Esp Med Nucl Imagen Mol
, vol.35
, Issue.2
, pp. 88-95
-
-
Mayoral, M.1
Fernandez-Martinez, A.2
Vidal, L.3
Fuster, D.4
Aya, F.5
Pavia, J.6
-
44
-
-
84943360371
-
Volume-based quantitative FDG PET/CT metrics and their association with optimal debulking and progression-free survival in patients with recurrent ovarian cancer undergoing secondary cytoreductive surgery
-
5916387
-
Vargas HA, Burger IA, Goldman DA, Micco M, Sosa RE, Weber W, et al. Volume-based quantitative FDG PET/CT metrics and their association with optimal debulking and progression-free survival in patients with recurrent ovarian cancer undergoing secondary cytoreductive surgery. Eur Radiol. 2015;25(11):3348–53. doi: 10.1007/s00330-015-3729-925916387
-
(2015)
Eur Radiol
, vol.25
, Issue.11
, pp. 3348-3353
-
-
Vargas, H.A.1
Burger, I.A.2
Goldman, D.A.3
Micco, M.4
Sosa, R.E.5
Weber, W.6
-
45
-
-
79952280663
-
HE4 and CA125 as a diagnostic test in ovarian cancer: prospective validation of the Risk of Ovarian Malignancy Algorithm
-
1304524
-
Van Gorp T, Cadron I, Despierre E, Daemen A, Leunen K, Amant F, et al. HE4 and CA125 as a diagnostic test in ovarian cancer: prospective validation of the Risk of Ovarian Malignancy Algorithm. Br J Cancer. 2011;104(5):863–70. doi: 10.1038/sj.bjc.660609221304524
-
(2011)
Br J Cancer
, vol.104
, Issue.5
, pp. 863-870
-
-
Van Gorp, T.1
Cadron, I.2
Despierre, E.3
Daemen, A.4
Leunen, K.5
Amant, F.6
-
46
-
-
0024522049
-
Response of patients in phase II studies of chemotherapy in ovarian cancer: implications for patient treatment and the design of phase II trials
-
713253
-
Blackledge G, Lawton F, Redman C, Kelly K, Response of patients in phase II studies of chemotherapy in ovarian cancer: implications for patient treatment and the design of phase II trials. Br J Cancer. 1989;59(4):650–3. 2713253
-
(1989)
Br J Cancer
, vol.59
, Issue.4
, pp. 650-653
-
-
Blackledge, G.1
Lawton, F.2
Redman, C.3
Kelly, K.4
-
47
-
-
0026086870
-
Second-line platinum therapy in patients with ovarian cancer previously treated with cisplatin
-
999708
-
Markman M, Rothman R, Hakes T, Reichman B, Hoskins W, Rubin S, et al. Second-line platinum therapy in patients with ovarian cancer previously treated with cisplatin. J Clin Oncol. 1991;9(3):389–93. doi: 10.1200/jco.1991.9.3.3891999708
-
(1991)
J Clin Oncol
, vol.9
, Issue.3
, pp. 389-393
-
-
Markman, M.1
Rothman, R.2
Hakes, T.3
Reichman, B.4
Hoskins, W.5
Rubin, S.6
-
48
-
-
4143087249
-
Duration of response to second-line, platinum-based chemotherapy for ovarian cancer: implications for patient management and clinical trial design
-
5284263
-
Markman M, Markman J, Webster K, Zanotti K, Kulp B, Peterson G, et al. Duration of response to second-line, platinum-based chemotherapy for ovarian cancer: implications for patient management and clinical trial design. J Clin Oncol. 2004;22(15):3120–5. doi: 10.1200/JCO.2004.05.19515284263
-
(2004)
J Clin Oncol
, vol.22
, Issue.15
, pp. 3120-3125
-
-
Markman, M.1
Markman, J.2
Webster, K.3
Zanotti, K.4
Kulp, B.5
Peterson, G.6
-
49
-
-
84875586086
-
A prognostic nomogram to predict overall survival in patients with platinum-sensitive recurrent ovarian cancer
-
3104722
-
Lee CK, Simes RJ, Brown C, Gebski V, Pfisterer J, Swart AM, et al. A prognostic nomogram to predict overall survival in patients with platinum-sensitive recurrent ovarian cancer. Ann Oncol. 2013;24(4):937–43. doi: 10.1093/annonc/mds53823104722
-
(2013)
Ann Oncol
, vol.24
, Issue.4
, pp. 937-943
-
-
Lee, C.K.1
Simes, R.J.2
Brown, C.3
Gebski, V.4
Pfisterer, J.5
Swart, A.M.6
-
50
-
-
84952630402
-
Prognostic factors modifying the treatment-free interval in recurrent ovarian cancer
-
6383827
-
Eng KH, Hanlon BM, Bradley WH, Szender JB, Prognostic factors modifying the treatment-free interval in recurrent ovarian cancer. Gynecol Oncol. 2015;139(2):228–35. doi: 10.1016/j.ygyno.2015.09.01126383827
-
(2015)
Gynecol Oncol
, vol.139
, Issue.2
, pp. 228-235
-
-
Eng, K.H.1
Hanlon, B.M.2
Bradley, W.H.3
Szender, J.B.4
-
51
-
-
80052681753
-
Early decline in cancer antigen 125 as a surrogate for progression-free survival in recurrent ovarian cancer
-
1840849
-
Lee CK, Friedlander M, Brown C, Gebski VJ, Georgoulopoulos A, Vergote I, et al. Early decline in cancer antigen 125 as a surrogate for progression-free survival in recurrent ovarian cancer. J Natl Cancer Inst. 2011;103(17):1338–42. doi: 10.1093/jnci/djr28221840849
-
(2011)
J Natl Cancer Inst
, vol.103
, Issue.17
, pp. 1338-1342
-
-
Lee, C.K.1
Friedlander, M.2
Brown, C.3
Gebski, V.J.4
Georgoulopoulos, A.5
Vergote, I.6
-
52
-
-
84901647383
-
Dynamic modeling in ovarian cancer: an original approach linking early changes in modeled longitudinal CA-125 kinetics and survival to help decisions in early drug development
-
4726614
-
Wilbaux M, Henin E, Oza A, Colomban O, Pujade-Lauraine E, Freyer G, et al. Dynamic modeling in ovarian cancer: an original approach linking early changes in modeled longitudinal CA-125 kinetics and survival to help decisions in early drug development. Gynecol Oncol. 2014;133(3):460–6. doi: 10.1016/j.ygyno.2014.04.00324726614
-
(2014)
Gynecol Oncol
, vol.133
, Issue.3
, pp. 460-466
-
-
Wilbaux, M.1
Henin, E.2
Oza, A.3
Colomban, O.4
Pujade-Lauraine, E.5
Freyer, G.6
-
53
-
-
84863626990
-
Normal serum CA125 half-life and normal serum nadir CA125 level in patients with ovarian cancers
-
2873097
-
Yoshikawa T, Takano M, Kita T, Kudoh K, Sasaki N, Kato M, et al. Normal serum CA125 half-life and normal serum nadir CA125 level in patients with ovarian cancers. Eur J Gynaecol Oncol. 2012;33(3):269–73. 22873097
-
(2012)
Eur J Gynaecol Oncol
, vol.33
, Issue.3
, pp. 269-273
-
-
Yoshikawa, T.1
Takano, M.2
Kita, T.3
Kudoh, K.4
Sasaki, N.5
Kato, M.6
-
54
-
-
84940202151
-
TP53 mutations, tetraploidy and homologous recombination repair defects in early stage high-grade serous ovarian cancer
-
5916844
-
Chien J, Sicotte H, Fan JB, Humphray S, Cunningham JM, Kalli KR, et al. TP53 mutations, tetraploidy and homologous recombination repair defects in early stage high-grade serous ovarian cancer. Nucleic Acids Res. 2015;43(14):6945–58. doi: 10.1093/nar/gkv11125916844
-
(2015)
Nucleic Acids Res
, vol.43
, Issue.14
, pp. 6945-6958
-
-
Chien, J.1
Sicotte, H.2
Fan, J.B.3
Humphray, S.4
Cunningham, J.M.5
Kalli, K.R.6
-
55
-
-
84924359778
-
Spatial and temporal heterogeneity in high-grade serous ovarian cancer: a phylogenetic analysis
-
5710373,..; ():
-
Schwarz RF, Ng CK, Cooke SL, Newman S, Temple J, Piskorz AM, et al. Spatial and temporal heterogeneity in high-grade serous ovarian cancer: a phylogenetic analysis. PLoS Med. 2015;12(2):e1001789. doi: 10.1371/journal.pmed.100178925710373
-
(2015)
PLoS Med
, vol.12
, Issue.2
, pp. e1001789
-
-
Schwarz, R.F.1
Ng, C.K.2
Cooke, S.L.3
Newman, S.4
Temple, J.5
Piskorz, A.M.6
-
56
-
-
84964767208
-
Detection of ubiquitous and heterogeneous mutations in cell-free DNA from patients with early-stage non-small-cell lung cancer
-
6823523
-
Jamal-Hanjani M, Wilson GA, Horswell S, Mitter R, Sakarya O, Constantin T, et al. Detection of ubiquitous and heterogeneous mutations in cell-free DNA from patients with early-stage non-small-cell lung cancer. Ann Oncol. 2016;27(5):862–7. doi: 10.1093/annonc/mdw03726823523
-
(2016)
Ann Oncol
, vol.27
, Issue.5
, pp. 862-867
-
-
Jamal-Hanjani, M.1
Wilson, G.A.2
Horswell, S.3
Mitter, R.4
Sakarya, O.5
Constantin, T.6
-
57
-
-
84907855592
-
Spatial and temporal diversity in genomic instability processes defines lung cancer evolution
-
5301630
-
de Bruin EC, McGranahan N, Mitter R, Salm M, Wedge DC, Yates L, et al. Spatial and temporal diversity in genomic instability processes defines lung cancer evolution. Science. 2014;346(6206):251–6. doi: 10.1126/science.125346225301630
-
(2014)
Science
, vol.346
, Issue.6206
, pp. 251-256
-
-
de Bruin, E.C.1
McGranahan, N.2
Mitter, R.3
Salm, M.4
Wedge, D.C.5
Yates, L.6
-
58
-
-
84903289929
-
Circulating tumor cells and response to chemotherapy in metastatic breast cancer: SWOG S0500
-
4888818
-
Smerage JB, Barlow WE, Hortobagyi GN, Winer EP, Leyland-Jones B, Srkalovic G, et al. Circulating tumor cells and response to chemotherapy in metastatic breast cancer: SWOG S0500. J Clin Oncol. 2014;32(31):3483–9. doi: 10.1200/JCO.2014.56.256124888818
-
(2014)
J Clin Oncol
, vol.32
, Issue.31
, pp. 3483-3489
-
-
Smerage, J.B.1
Barlow, W.E.2
Hortobagyi, G.N.3
Winer, E.P.4
Leyland-Jones, B.5
Srkalovic, G.6
-
59
-
-
84940792112
-
A Bayesian adaptive design for biomarker trials with linked treatments
-
6263479
-
Wason JM, Abraham JE, Baird RD, Gournaris I, Vallier AL, Brenton JD, et al. A Bayesian adaptive design for biomarker trials with linked treatments. Br J Cancer. 2015;113(5):699–705. doi: 10.1038/bjc.2015.27826263479
-
(2015)
Br J Cancer
, vol.113
, Issue.5
, pp. 699-705
-
-
Wason, J.M.1
Abraham, J.E.2
Baird, R.D.3
Gournaris, I.4
Vallier, A.L.5
Brenton, J.D.6
|